Viatris
VTRS
$17.63
+0.40%
Viatris Inc. is a global healthcare company formed in November 2020 through the combination of Pfizer's Upjohn unit and Mylan, specializing in generic and specialty pharmaceuticals. It operates across more than 165 countries, with a portfolio that includes generics, biosimilars, and established legacy brands such as Lipitor, Norvasc, Lyrica, and Viagra. As one of the largest generic drug manufacturers worldwide, Viatris holds a distinct competitive position in the off-patent drug market, focusing on dermatology, ophthalmology, and gastroenterology for future innovation. The current investor narrative centers on the company's strategic transformation, including portfolio optimization, debt reduction, and a renewed focus on high-growth areas, while navigating the challenges of patent expirations and pricing pressures in the generics industry.…
VTRS
Viatris
$17.63
Investment Opinion: Should I buy VTRS Today?
Based on the analysis, Viatris is rated a 'Buy' with a thesis that the company's return to revenue growth, undervaluation on sales and forward earnings, and positive analyst sentiment outweigh the risks of negative earnings and high debt. The consensus recommendation is 'Buy' with an average target price of $17.94, implying a modest upside of 2.2%, but the potential for re-rating is significant if the company meets its growth targets. Key supporting data include the 8.1% YoY revenue growth in Q1 2026, a PS ratio of 1.02x versus the industry average of 3.5x, a forward PE of 6.69x, and TTM free cash flow of $1.71 billion. These metrics indicate that the stock is undervalued relative to its growth potential and cash generation capabilities.
Sign up to view all
VTRS 12-Month Price Forecast
The AI assessment is bullish on Viatris, driven by its return to revenue growth, attractive valuation metrics, and positive analyst sentiment. The company's focus on complex generics and biosimilars positions it well for future growth, and its free cash flow generation provides a solid foundation. However, the medium confidence reflects the risks of negative earnings and high debt, which could derail the thesis if not addressed. The stance would be upgraded to high confidence if the company demonstrates sustained profitability and margin improvement, while a downgrade would occur if revenue growth decelerates or debt levels increase significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Viatris's 12-month outlook, with a consensus price target around $17.94 and implied upside of +1.7% versus the current price.
Average Target
$17.94
0 analysts
Implied Upside
+1.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$12 - $23
Analyst target range
Viatris has coverage from 8 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 2.2 (where 1 is Strong Buy and 5 is Sell). The average target price is $17.94, implying a modest upside of 2.2% from the current price of $17.56. The target range spans from $12.00 (low) to $23.00 (high), indicating a wide dispersion in expectations. The high target suggests potential for significant upside if the company's growth initiatives succeed, while the low target reflects concerns about competitive pressures and debt levels. Recent ratings actions have been mostly positive, with upgrades from Argus Research (Hold to Buy) and reaffirmations of Overweight from Barclays, though JP Morgan and Piper Sandler remain Neutral, indicating a balanced but cautiously optimistic outlook.
Bulls vs Bears: VTRS Investment Factors
Viatris presents a compelling turnaround story with strong revenue growth, a discounted valuation, and positive analyst sentiment, but it is weighed down by persistent profitability issues, high debt, and limited near-term upside. The bull case is supported by the return to growth and undervaluation, while the bear case is underscored by negative earnings and margin pressures. Currently, the bull side has stronger evidence given the momentum and strategic focus, but the key tension lies in whether the company can sustain its growth trajectory and improve margins to justify its valuation. If revenue growth continues and margins expand, the stock could re-rate higher; if not, the current price may be overextended.
Bullish
- Strong Revenue Growth Return: Q1 2026 revenue grew 8.1% YoY to $3.517 billion, a clear inflection after a period of stagnation. This growth is driven by the Brands segment, which contributed $2.332 billion (66.3% of total revenue), indicating a solid foundation for continued expansion.
- Undervalued on Sales and Forward Earnings: With a PS ratio of 1.02x versus the industry average of 3.5x, and a forward PE of 6.69x, the stock trades at a significant discount. This suggests the market is pricing in substantial earnings recovery, offering upside if the company meets expectations.
- Massive Price Appreciation and Momentum: The stock is up 100.9% over the past year, far outpacing the S&P 500's 18.2% gain. It sits at 94.5% of its 52-week range, indicating strong momentum and investor confidence in the company's turnaround strategy.
- Positive Analyst Sentiment and Upgrades: The consensus recommendation is 'Buy' with a mean score of 2.2, and recent actions include upgrades from Argus Research (Hold to Buy) and reaffirmations of Overweight from Barclays. This reflects growing optimism among analysts about Viatris's prospects.
Bearish
- Negative Earnings and Thin Margins: Trailing twelve-month EPS is -$0.24, and the net margin is -24.6%, reflecting persistent profitability challenges. Even in Q1 2026, operating income was -$79.7 million, indicating ongoing operational inefficiencies.
- High Debt Levels and Interest Burden: Debt-to-equity stands at 1.0x, and interest expenses were $120.1 million in Q1 2026 alone. This leverage increases financial risk and limits flexibility, especially if earnings fail to recover as expected.
- Limited Upside to Analyst Targets: The average analyst target price is $17.94, implying only 2.2% upside from the current price of $17.56. This suggests the stock may be fairly valued or even slightly ahead of expectations, reducing potential returns.
- Revenue Volatility and Segment Dependence: Revenue has been uneven, with Q4 2025 at $3.704 billion, Q3 2025 at $3.760 billion, and Q2 2025 at $3.582 billion, showing a declining trend before Q1 2026's rebound. The heavy reliance on the Brands segment (66.3% of revenue) exposes the company to patent expirations and pricing pressures.
VTRS Technical Analysis
Viatris is in a strong uptrend, with the stock price at $17.56 as of July 31, 2026, up 100.9% over the past year. The current price sits at 94.5% of its 52-week range (low of $8.63, high of $18.07), indicating proximity to the upper end of its trading band. This positioning suggests robust momentum, though it also raises the risk of overextension, especially after such a substantial rally. The stock's 1-year change of +100.9% significantly outperforms the S&P 500's +18.2%, highlighting Viatris's relative strength.
Beta
0.89
0.89x market volatility
Max Drawdown
-19.6%
Largest decline past year
52-Week Range
$9-$18
Price range past year
Annual Return
+100.1%
Cumulative gain past year
| Period | VTRS Return | S&P 500 |
|---|---|---|
| 1m | +5.6% | +1.7% |
| 3m | +13.6% | +4.7% |
| 6m | +22.8% | +10.4% |
| 1y | +100.1% | +21.9% |
| ytd | +41.5% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VTRS Fundamental Analysis
Viatris's revenue trajectory shows a mixed but improving picture. In Q1 2026, revenue was $3.517 billion, up 8.1% year-over-year, marking a return to growth after a period of stagnation. However, the multi-quarter trend reveals volatility: Q4 2025 revenue was $3.704 billion, Q3 2025 was $3.760 billion, and Q2 2025 was $3.582 billion, indicating a slight decline from the prior year's levels. The growth is driven by the Brands segment, which contributed $2.332 billion (66.3% of total revenue), while Generics contributed $1.177 billion (33.5%). The company's focus on complex generics and biosimilars is expected to support future growth, but the overall trajectory remains uneven, with the most recent quarter showing a positive inflection.
Quarterly Revenue
$3.5B
2026-03
Revenue YoY Growth
+8.1%
YoY Comparison
Gross Margin
32.9%
Latest Quarter
Free Cash Flow
$1.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VTRS Overvalued?
Given that Viatris's trailing twelve-month net income is negative (EPS of -$0.24), the price-to-sales (PS) ratio is the most appropriate valuation metric. The current PS ratio is 1.02x, which is lower than the industry average of 3.5x for drug manufacturers, indicating a significant discount. The forward PE ratio of 6.69x suggests the market expects earnings to recover strongly, implying a potential re-rating if the company meets these expectations. The EV/Sales ratio of 2.26x further confirms a discounted valuation relative to peers, but this is partly justified by the company's high debt levels and historical earnings volatility.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~31x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-70.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, Viatris faces significant risks from its negative earnings and thin margins. The trailing twelve-month net income is -$0.24 per share, and the net margin is -24.6%, indicating that the company is not generating consistent profits. Operating income was negative in Q1 2026 at -$79.7 million, and the gross margin of 35.1% is below industry norms, suggesting pricing pressures and cost inefficiencies. Additionally, the debt-to-equity ratio of 1.0x and interest expenses of $120.1 million per quarter add a substantial fixed cost burden, which could strain cash flows if revenue growth falters. The company's reliance on the Brands segment for 66.3% of revenue exposes it to patent expirations and generic competition, which could erode revenue stability.
FAQ
The key risks of holding VTRS include financial risks from negative earnings and high debt, with a debt-to-equity ratio of 1.0x and interest expenses of $120.1 million per quarter. Competitive risks include patent expirations on key brands and pricing pressures in generics, which could erode revenue. Macro risks include sensitivity to interest rates, as higher rates increase debt costs, and sector rotation away from healthcare. Company-specific risks include execution risks in the turnaround strategy, such as failing to achieve cost synergies or delays in product launches. The most severe risk is a continued inability to generate positive net income, which could lead to a de-rating and a decline to the 52-week low of $8.63, representing a 50.9% downside.
The VTRS stock forecast over the next 12 months is mixed, with a base case probability of 50% targeting a range of $16.00 to $18.00, aligning with the average analyst target of $17.94. The bull case, with a 30% probability, targets $20.00 to $23.00, driven by sustained growth and margin improvement. The bear case, with a 20% probability, targets $12.00 to $14.00, reflecting risks of competitive pressures and earnings disappointments. The most likely scenario is the base case, where the stock trades near its current level with modest upside, as the market awaits clearer evidence of profitability.
VTRS is undervalued on a sales basis, with a PS ratio of 1.02x compared to the industry average of 3.5x, and on a forward earnings basis, with a forward PE of 6.69x. However, the trailing PE is negative due to losses, and the EV/EBITDA is -70.6x, reflecting the lack of current profitability. The market is pricing in a strong earnings recovery, as evidenced by the low forward PE. Relative to its own history, the stock has re-rated significantly, but it still trades at a discount to peers. The valuation implies that the market expects Viatris to return to profitability and grow earnings, which is a reasonable assumption given the recent revenue growth.
VTRS is a good buy for investors with a higher risk tolerance, given its discounted valuation and growth potential. The stock trades at a PS ratio of 1.02x versus the industry average of 3.5x, and a forward PE of 6.69x, indicating undervaluation. However, the average analyst target price of $17.94 implies only 2.2% upside, so the near-term reward is limited. The biggest risk is the company's negative earnings and high debt, which could lead to further downside if growth stalls. For those who believe in the turnaround story, it could be a rewarding investment, but it is not without significant risk.
VTRS is more suitable for long-term investment, given its turnaround nature and the time needed for strategic initiatives to bear fruit. The stock has a beta of 0.902, indicating lower volatility than the market, but it has experienced significant price swings, with a 52-week range of $8.63 to $18.07. The company pays a dividend yield of 3.85%, providing some income while waiting for capital appreciation. Earnings visibility is improving with the return to revenue growth, but profitability is not yet consistent. A minimum holding period of 2-3 years is recommended to allow the company to execute its transformation and for the market to recognize its value.